·
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9
billion and operating profit of KRW 144.0 billion
(BUSINESS
WIRE)--Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to
innovations in biopharmaceuticals and biotechnology, today announced its
financial results for the first quarter of fiscal year 2026.
“Samsung
Bioepis delivered solid growth this quarter driven by continued momentum across
our biosimilar portfolio," said Kyung-Ah Kim, President and Chief
Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening
our position through new global partnerships and continued portfolio expansion.
As we mark the 10th anniversary of the
launch of our first biosimilar in Europe, we remain focused on building on our
legacy while investing strategically to support long-term growth. We remain committed
to delivering sustainable value for our shareholders.”
First
Quarter 2026 Results
On
a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a
revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion.
Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3
billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.
First
quarter growth surpassed the January 2025 guidance by more than 10%, reflecting
stronger-than-expected performance across the business.
Samsung
Epis Holdings posted a consolidated revenue of KRW 453.9 billion and operating
profit of KRW 90.5 billion. Non-cash accounting adjustments, including
amortization of purchase price allocation (PPA)-related development costs, are
reflected in consolidated revenue and operating profit, following a
consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6
billion in November and December 2025.
|
[Samsung Bioepis
Earnings, KRW billion] |
|
|||
|
|
Q1’24 |
Q1’25 |
Q1’26 |
YoY Change |
|
Revenue |
280.1 |
400.6 |
454.9 |
+54.3 (+14%) |
|
Operating Profit |
38.1 |
127.9 |
144.0 |
+16.1 (+13%) |
Business
Updates
·
In
October 2025, Samsung Bioepis entered into a private label partnership with CVS
Caremark, the Pharmacy Benefit Manager (PBM) division of CVS Health, for
OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1.
·
BENEPALI™
(etanercept), Samsung Bioepis’ first biosimilar in Europe, continues to
maintain its leadership position in the market as it celebrates its 10th anniversary in
Europe.
·
In
March, Samsung Bioepis expanded its development and commercialization
partnership with Sandoz, on up to five biosimilar candidates including SB36, a
biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets.
·
Also
in March, a Phase 1 first-in-human clinical trial for Samsung Bioepis’s first
novel antibody-drug conjugate (ADC) candidate, SBE303, has begun. Following the
announcement, the company also presented a poster presentation of its
nonclinical data at the American Association for Cancer Research (AACR) 2026 on
April 20th which demonstrates
its encouraging efficacy, safety, tolerability and a promising ability to work
in combination with existing immuno-oncology therapies.
·
Samsung
Bioepis’s second novel ADC candidate, SBE313, is currently in nonclinical
development in collaboration with Phrontline Biopharma.
Disclaimer
This
document contains ‘forward-looking statements’ regarding future expectations,
projections, plans, and anticipation. ‘Forward-looking statements’ are matters
that pertain to the Company’s future business and financial performance, and
are subject to uncertainties such as trends in domestic and international
financial markets, including but not limited to fluctuations in exchange rates
and/or interest rates.
‘Forward-looking
statements,’ by their nature, addresses matters that may be uncertain; actual
results may be materially different from those expressed in this document.
About
Samsung Epis Holdings Co., Ltd.
As
an investment holdings company dedicated to biopharmaceuticals and
biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder
value through proactive R&D and investment and optimize business strategies
for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings
continues to embrace future challenges and drive innovation by identifying new
growth drivers and strengthening global collaboration platforms, thereby laying
a solid foundation for the continued growth of its subsidiaries. For more
information about Samsung Epis Holdings, please visit: www.samsungepisholdings.com.
About
Samsung Bioepis Co., Ltd.
Established
in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing
healthcare that is accessible to everyone. Through innovations in product
development and a firm commitment to quality, Samsung Bioepis aims to become
the world's leading biopharmaceutical company. Samsung Bioepis continues to
advance a broad pipeline of biologic candidates that cover a spectrum of
therapeutic areas, including immunology, oncology, ophthalmology, hematology,
nephrology, neurology, and endocrinology. For more information, please
visit www.samsungbioepis.com and follow us on LinkedIn and X.
About
Epis NexLab Co., Ltd.
Established
in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is
committed to driving innovation through the development of next-generation
biotechnology platforms. By transforming highly scalable peptide-related
technologies into development platforms, Epis NexLab is focused on the
discovery of innovative treatment modalities for the development of multiple
therapeutic candidates targeting a wide range of diseases. For more information
about Epis NexLab, please visit: www.samsungepisholdings.com.
Reference
1 Prolia is a
registered trademark of Amgen Inc.
View source version on
businesswire.com: https://www.businesswire.com/news/home/20260422191520/en/
Permalink
https://www.aetoswire.com/en/news/2304202654496
Contacts
Media
Contact
Yoon Kim, yoon1.kim@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com
No comments:
Post a Comment